The threat from the pink corner

Annals of Medicine

Volumn 35, Issue 4, 2003, Pages 226-234

  Livermore, David M ^a  

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

lactamase; Acinetobacter; Antibiotic resistance; Gram negative bacteria; Metalio lactamases; Multi resistance; Pseudomonas

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; ERTAPENEM; GEMIFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; TETRACYCLINE DERIVATIVE; TIMENTIN; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; BURKHOLDERIA GLADIOLI; CYSTIC FIBROSIS; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; IMMUNE DEFICIENCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 0038727786     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890310001609     Document Type: Review

References (55)

1. Livermore DM, Mushtaq S, James D, Potz N, Walker RA, Charlett A, et al. In-vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. Int J Antimicrob Agents 2003: in press.
2. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320: 213-6.
3. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119(2 Suppl): 397S-404S.
4. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002; 51: 565-7.
5. Gruneberg RN. Global surveillance through PROTEKT: the first year. J Chemother 2002; 14 Suppl 3: 9-16.
6. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs 2002; 3: 218-24.
7. Johnson AP, Livermore DM, Tillotson GS. Antimicrobial susceptibility of gram-positive bacteria: what's current, what's anticipated? J Hosp Infect 2001; 49 Suppl A: S3-11.
8. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2002; 2: 404-15.
9. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa, our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
10. Henwood CJ, Livermore DM, James D, Warner M, Pseudomonas Study Group. Anrimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother 2001; 47: 789-99.
11. Chen HY, Yuan M, Ibrahim-Elmagboul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 35: 521-34.
12. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-4.
13. Nordmann P, Poirel L. Emerging carbapenemases in Gramnegative aerobes. Clin Microbiol Infect 2002; 8: 321-31.
14. Danel F, Hall LM, Gür D, Akalin HE, Livermore DM. Transferable production of PER-1 β-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 35: 281-94.
15. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Des 1999; 5: 865-79.
16. Tsakris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000; 38: 1290-2.
17. Gibb AP, Tribuddharat C, Moore RA, Louie TJ, Krulicki W, Livermore DM, et al. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla (IMP) allele, bla (IMP-7). Antimicrob Agents Chemother 2002; 46: 255-8.
18. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960-7.
19. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
20. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148-65.
21. Afzal-Shah M, Woodford N, Livermore DM. Characterization of: OXA-25, -26 and -27 molecular Class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45: 583-8.
22. Bou G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lacramases. J Clin Microbiol 2000; 38: 3299-305.
23. Lopez-Otsoa F, Gallego L, Towner KJ, Tysall L, Woodford N, Livermore DM. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in Northern Spain. J Clin Microbiol 2002; 40: 4741-3.
24. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence R, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the United Kingdom and in-vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
25. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 1946-52.
26. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34: 1425-30.
27. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 793-802.
28. Bello H, Dominguez M, Gonzalez G, Zemelman R, Mella S, Young HK, et al. In-vitro activities of ampicillin, sulbactam and a combination of ampicillin and sulbactam against isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated in Chile between 1990 and 1998. J Antimicrob Chemother 2000; 45: 712-3.
29. Bonfiglio G, Livermore DM. Effect of media composition on the susceptibility of Xanthomonas maltophilia to β-lactam antibiotics. J Antimicrob Chemother 1991; 28: 837-42.
30. VanCouwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epiderniol 1997; 18: 316-21.
31. Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000; 32: 651-6.
32. Munoz Bellido JL, Garcia-Rodriguez JA. Aztreonam-clavulanic acid synergy does not mean extended-spectrum β-lactamase in Stenotrophomonas maltophilia. J Antimicrob Chemother 1998; 41: 493-4.
33. Garcia Sanchez JE, Vazquez Lopez ML, Blazquez de Castro AM, Perez Simon JA, Gutierrez NG, Martin IT, et al. Aztreonam/clavulanic acid in the treatment of serious infections caused by Stenotrophomonas maltophilia in neutropenic patients: case reports. J Chemother 1997; 9: 238-40.
34. Downhour NP, Petersen EA, Krueger TS, Tangella KV, Nix DE. Severe cellulitis/myositis caused by Stenotrophomonas maltophilia. Ann Pharmacother 2002; 36: 63-6.
35. Ho PL, Cheung TK, Yam WC, Yuen KY. Characterization of a laboratory-generated variant of BPS β-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime. J Antimicrob Chemother 2002; 50: 723-6.
36. Niumsup P, Wuthiekanun V. Cloning of the class D β-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. J Antimicrob Chemother 2002; 50: 445-55.
37. Cheung TK, Ho PL, Woo PC, Yuen KY, Chau PY. Cloning and expression of class A β-lactamase gene blaA (BPS) in Burkholderia pseudomallei. Antimicrob Agents Chemother 2002; 46: 1132-5.
38. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001; 3: 255-64.
39. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 1999; 43: 465-70.
40. Baxter IA, Lambert PA. Isolation and partial purification of a carbapenem-hydrolysing metallo-β-lactamase from Pseudornonas cepacia. FEMS Microbiol Lett 1994; 122: 251-6.
41. Pitt TL, Kaufmann ME, Patel PS, Benge LC, Gaskin S, Livermore DM. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol 1996; 44: 203-10.
42. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206-12.
43. Koh TH, Sng LH, Babini GS, Woodford N, Livermore DM, Hall LMC. Carbapenem-resistant Klebsiella pnuemoniae in Singapore producing IMP-1 β-lactamase and lacking an outer membrane protein. Antimicrob Agents Chemother 2001; 45: 1939-40.
44. Yan JJ, Ko WC, Chuang CL, Wu JJ. Metallo-β-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J Antirnicrob Chemother 2002; 50: 503-11.
45. Yan JJ, Ko WC, Tsai SH, Wu HM, Wu JJ. Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan. J Clin Microbiol 2001; 39: 4433-9.
46. Hawkey PM, Xiong J, Ye H, Li H, M'Zali FH. Occurrence of a new metallo-β-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett 2001; 194: 53-7.
47. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45: 1151-61.
48. Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 2002; 5: 119-25.
49. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000; 45: 363-5.
50. Critchley IA, Basker MJ, Edmondson RA, Knott SJ. Uptake of a catecholic cephalosporin by the iron transport system of Escherichia coli. J Antimicrob Chemother 1991; 28: 377-88.
51. Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Paggi AM, Petrelli E, et al. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Cbemother 2000; 46: 807-10.
52. Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Fortuna M, Drenaggi D, et al. In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2000; 44: 1716-9.
53. Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother 1999; 44: 641-5.
54. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105-16.
55. Payne DJ, Du W, Bateson JH. β-Lactamase epidemiology and the utility of established and novel β-lactamase inhibitors. Expert Opin Investig Drugs 2000; 9: 247-61.